, an endogenous ligand for G protein-coupled receptors NPBWR1 (GPR7) and NPBWR2 (GPR8), has been detected in neurons in limbic and reticular activating system areas known to be important in arousal, as well as hypothalamic nuclei known to be important in food and water intake and the neuroendocrine response to stress. In rat, central administration of NPW increased mean arterial pressure (MAP) and behaviors associated with locomotion and grooming. We hypothesized that the NPW-induced increase in MAP was secondary to those increases in physical activity. Since peptides that stimulate arousal have been shown to increase sympathetic activity (e.g., orexin), we tested the ability of the mixed ␣ 1-and ␣ 2-adrenergic antagonist, phentolamine, to block the NPW-23-induced rise in MAP. Phentolamine pretreatment abrogated the NPWinduced MAP increase. However, we noticed the animals no longer exhibited NPW-associated behavioral arousal when pretreated with phentolamine. Anesthesia also blocked the NPW-induced increase in MAP, although the animals still were able to respond with an increase in MAP to centrally administered ANG II. Additionally, pretreatment with an orexin type 1 receptor antagonist significantly reduced the behavioral action of NPW-23 and completely blocked the peptide's action to increase MAP, suggesting that orexin neurons are downstream targets of NPW. Our results suggest that NPW increased MAP secondary to increased behavioral arousal. neuropeptide W; GPR7; GPR8; mean arterial pressure; behavioral arousal TWO NOVEL GENES THAT ENCODE the orphan G protein-coupled receptors GPR7 and GPR8 were originally cloned from human genomic DNA by degenerative polymerase chain reaction using primers based on sequences of the ␦-opioid and somatostatin receptors. O'Dowd and colleagues used Northern blot analysis to identify the expression of these genes in human brain and in situ hybridization histochemistry to detect the presence of gene transcripts in discrete hypothalamic areas of the mouse brain (8). Subsequently, Lee et al. (5) reported an even wider distribution of transcripts encoding GPR7 in mouse, human, and rat brain. In particular, GPR7 gene transcripts were observed in rat hypothalamus in the paraventricular, supraoptic, arcuate, suprachiasmatic, and ventromedial and dorsomedial nuclei (5). All of these nuclei contribute to the neuroendocrine regulation of anterior pituitary hormone secretion and, as well, are involved in cardiovascular regulation (17). In contrast, the gene encoding GPR8 has not been detected in rat or mouse brain (5).
TWO NOVEL GENES THAT ENCODE the orphan G protein-coupled receptors GPR7 and GPR8 were originally cloned from human genomic DNA by degenerative polymerase chain reaction using primers based on sequences of the ␦-opioid and somatostatin receptors. O'Dowd and colleagues used Northern blot analysis to identify the expression of these genes in human brain and in situ hybridization histochemistry to detect the presence of gene transcripts in discrete hypothalamic areas of the mouse brain (8) . Subsequently, Lee et al. (5) reported an even wider distribution of transcripts encoding GPR7 in mouse, human, and rat brain. In particular, GPR7 gene transcripts were observed in rat hypothalamus in the paraventricular, supraoptic, arcuate, suprachiasmatic, and ventromedial and dorsomedial nuclei (5) . All of these nuclei contribute to the neuroendocrine regulation of anterior pituitary hormone secretion and, as well, are involved in cardiovascular regulation (17) . In contrast, the gene encoding GPR8 has not been detected in rat or mouse brain (5) .
The endogenous ligand for these receptors was identified as neuropeptide W (NPW) in 2002, when Shimomura et al. (14) isolated and sequenced two endogenous forms of NPW, NPW-30, and NPW-23 (14) . NPW-23 and the COOH terminally extended form, NPW-30, bind with similar affinity to GPR7 and GPR8 (14) . Predicting that these peptides would alter hypothalamic function, Shimomura et al. (14) administered 10 nmol NPW-23 intracerebroventricularly and demonstrated an increase in food intake and prolactin secretion. These preliminary data motivated our laboratory to examine the possibility that NPW might act in the hypothalamus, or in the adenohypophysis, to alter anterior pituitary hormone release. In 2003, we reported the ability of exogenous NPW-23 to significantly elevate circulating levels of prolactin (PRL) and corticosterone and to significantly lower plasma GH levels when administered intracerebroventricularly in conscious male rats. We also observed that food and water intake were stimulated by intracerebroventricular administration of 3.0 nmol NPW-23 (1) . The ability of centrally administered NPW to activate the hypothalamo-pituitary-adrenal (HPA) axis in conscious male rats was blocked by intravenous pretreatment with a corticotropin-releasing hormone (CRH) antagonist, suggesting an action of NPW on CRH-producing neurons in the parvocellular division of the paraventricular nucleus (PVN). Indeed, in hypothalamic slice preparations, bath application of NPW resulted in depolarization and an increase in the spike frequency of neuroendocrine PVN neurons (22) . These data suggest that endogenous NPW may play a role in the hypothalamic response to stress. Parvocellular PVN neurons also project directly to the spinal cord and medulla and contribute to the control of sympathetic outflow (3) . To investigate the potential role of NPW in central cardiovascular control mechanisms, we examined the effect of intracerebroventricular NPW-23 administration on mean arterial pressure (MAP). Here, we report the ability of centrally administered NPW-23 to increase MAP in conscious, unrestrained rats, but not anesthetized animals. We suggest that the ability of NPW to increase MAP in conscious rats is secondary to its effect on behavioral arousal.
MATERIALS AND METHODS
Animals. All procedures and protocols have been approved by Saint Louis University Animal Care and Use Committee. Adult male rats (Harlan Sprague-Dawley; 250 -300 g) were housed individually following all surgical procedures with free access to food and water under controlled conditions (23-25°C, lights on 0600 -1800).
Surgery. Animals were anesthetized with a mixture of ketamine (60 mg/ml; Ketaset, Fort Dodge Animal Health, Fort Dodge, IA) and xylazine (8 mg/ml; TranquiVed, VedCo, Saint Joseph, MO) at a dose of 0.1 ml/100 g body wt, as previously described (23) . A stainlesssteel cannula (23 gauge, 17 mm) was implanted into the right lateral cerebroventricle using a stereotaxic device. Rats were observed daily to ensure health and recovery to presurgery body weight for at least 5 days before further surgery or experimentation. Placement and patency of the cannula were confirmed by the dipsogenic effect of ANG II (50 pmol). For cardiovascular experiments and behavior studies requiring phentolamine administration, a second cannula [polyethylene (PE)-50] was implanted into the left carotid artery under ketamine-xylazine anesthesia, as previously described (23) . The carotid cannula was filled with heparinized saline (200 U/ml in 0.9% NaCl) and exteriorized between the shoulder blades.
Behavior in conscious animals. Animals bearing intracerebroventricular cannulas were moved to a quiet testing room (between 0600 and 0700) and allowed to rest in their home cages for at least 1 h. Individual rats then were placed in a Plexiglas recording chamber (width 44 ϫ 44 cm, depth 20 cm; Opto-Max Activity Monitor; Columbia Instruments, Columbus, OH) and were habituated to the chamber for 1 h, during which time baseline activity was monitored. At the end of the habituation period, the lid was removed from the cage, and a 28-gauge injection needle was inserted via the implanted intracerebroventricular cannula, extending 1 mm past the cannula tip. Using a Hamilton syringe, two microliters of isotonic saline (vehicle control, sterile 0.9% NaCl) or saline containing 0.3, 1.0, or 3.0 nmol NPW-23 (Phoenix Pharmaceuticals, Burlingame, CA) was injected over a 30-s interval, and then the cage lid was replaced. Activity was monitored for an additional 120 min. For the phentolamine behavior study, animals were allowed to habituate to the room for at least 1 h. Rats were placed in the recording chamber and habituated for 1 h, while monitoring baseline activity. At the end of the habituation period, the lid was removed, and phentolamine-HCl (10 mg/kg body wt in 0.9% NaCl, Sigma-Aldrich, St. Louis, MO) or saline was injected intra-arterially 15 min before central injection of saline, or saline containing 1.0 nmol NPW-23 or 50 pmol ANG II (Phoenix Pharmaceuticals). In a final experiment designed to examine the possible recruitment of endogenous orexin neurons by NPW-23, the injection syringe was first loaded with one microliter saline containing 1.0 nmol NPW-23 and then one microliter of injection vehicle (1:20 DMSO:Saline) or injection vehicle containing 3.0 nmol orexin type 1 receptor (OX 1R) antagonist (SB-408124; Sigma Aldrich), as previously described (11) . In this manner, the injection vehicle alone or containing the OX1R antagonist was injected first, followed 15 s later by NPW-23. Activity was monitored for an additional 60 min. The activity monitor was configured as a two-dimensional array with rearing, with 16 beams/array separated by 1-inch intervals (beam diameter 0.125 inches). The calibration for "plane break delay" was set at 1 s, and the ambulatory threshold was 1 inch/s. The margin was set at 1 inch. Data were calculated in 10-min sampling intervals. The first six intervals served as the habituation phase during which time the animals initially explored the cage and then resumed normal behavioral activity for the time of day (lights on). We evaluated total activity (defined as total beam breaks), ambulatory activity (total beam breaks in the horizontal plane), and duration of stereotypy (time spent in repeated beam breaks while scratching and grooming).
Blood pressure in conscious animals. Cardiovascular experiments were conducted the day after carotid implantation. On the day of the experiment, animals were habituated to a quiet room for at least 2 h. The carotid cannula was flushed with heparinized saline (200 U/ml in 0.9% NaCl) and connected to a pressure transducer (DigiMed Blood Pressure Analyzer, Micro-Med, Louisville, KY). Baseline MAP was recorded for at least 30 min at 1-min intervals. For all experiments, preinjection baseline was calculated as the average MAP for 10 min before intracerebroventricular injections of saline or NPW-23. To test the cardiovascular effects of centrally administered NPW-23, rats were treated intracerebroventricularly with vehicle or vehicle containing 0.3, 1.0, or 3.0 nmol NPW-23. MAP was recorded for at least 45 min at 1-min intervals. To determine the potential role of sympathetic activation in mediating NPW-induced MAP increase, rats were pretreated intra-arterially (22) with the ␣-adrenergic antagonist phentolamine-HCl (10 mg/kg body wt in 0.9% NaCl; Sigma-Aldrich) or saline 15 min before central injection of saline or saline containing 1.0 nmol NPW-23. In a final experiment, the OX1R antagonist, SB-408124, or vehicle was injected intracerebroventricularly 15 s prior to 1.0 nmol NPW-23, as described above, and MAP was monitored for 45 min at 1-min intervals.
Blood pressure in anesthetized animals. Animals were anesthetized with urethane (1.4 g/kg body wt; Sigma-Aldrich), and 0.1-ml ketamine/xylazine and a cannula were implanted into the carotid artery, as previously described (22) . A stainless-steel cannula (23 gauge, 17 mm) was immediately implanted into the right lateral cerebroventricle using a stereotaxic device. The carotid cannula was flushed with heparinized saline (200 U/ml in 0.9% NaCl) and connected to a pressure transducer. Baseline MAP was recorded for at least 30 min at 1-min intervals before intracerebroventricular injections of saline alone or saline containing 1.0 or 3.0 nmol NPW-23.
Statistical analyses. Behavioral data were analyzed by one-way ANOVA and Scheffé's multiple comparison. Homogeneity of variance was established using the S test. Significance was assigned to results that occurred with less than 5% probability. Blood pressure data were analyzed using a nonparametric test (Mann Whitney U), because the data were transformed to reflect the change from preinjection baseline to account for natural differences in resting MAP between animals (25).
RESULTS
In conscious, freely moving rats, all three doses (0.3 nmol, 1.0 nmol, and 3.0 nmol) of NPW-23 caused significant increases in MAP (Fig. 1, A and B) . The rise began within 2 min following intracerebroventricular injection, peaked at ϳ15 min, and was sustained for ϳ30 min at all three doses. The greatest peak change from baseline, of ϳ18 mmHg (average preinjection baselines: saline ϭ 129.2 Ϯ 3. While recording MAP, we observed a general increase in the spontaneous activity of the rats following central administration of NPW-23. Therefore, we placed rats in an Opto-Max behavior-monitoring device, and, after 1 h of habituation, administered saline alone intracerebroventricularly or saline containing 0.3 nmol, 1.0 nmol, or 3.0 nmol NPW-23. Rats that received either 1.0 or 3.0 nmol NPW-23 demonstrated a significant increase in total activity, ambulatory activity, and duration of stereotypy (Fig. 2, A-C) . These increases were already observed within the first 10-min observation period following intracerebroventricular injection and were sustained for ϳ20 min. The greatest increase in activity occurred in animals administered 1.0 nmol NPW-23.
Since peptides that stimulate arousal have been shown to increase sympathetic activity [e.g., orexin (12, 15, 16) ], we tested the ability of the mixed ␣ 1 -and ␣ 2 -adrenergic antagonist, phentolamine, to block the NPW-23-induced rise in MAP. Phentolamine HCl (10 mg/kg) or saline were given intraarterially 15 min prior to intracerebroventricular injection of 1.0 nmol NPW-23. Central administration of NPW-23 (following intra-arterial saline vehicle pretreatment) again led to an increase in MAP (Fig. 3A) . Rats that were pretreated with phentolamine had a lower resting MAP as expected (average (Fig. 3B) . The dose of phentolamine used in this study did not inhibit the vascular reactivity of the animals, as rats that were pretreated with phentolamine responded to a pressor dose of intra-arterially administered ANG II (data not shown), as previously described (23) .
To address the hypothesis that the NPW-induced increase in MAP is due to behavioral arousal, we measured NPW-induced MAP changes in urethane-anesthetized animals. Central administration of 1.0 or 3.0 nmol NPW-23 failed to increase MAP in urethane-anesthetized animals (Fig. 4) . The dose of urethane used in these studies did not inhibit the ability of the animals to respond to peptides known to increase MAP as a result of an action to increase sympathetic activity [e.g., ANG II, (2)]. All animals used in this study were able to mount a pressor response of ϳ10 mmHg in response to central administration of a 50-pmol dose of ANG II (data not shown).
While recording MAP in the phentolamine study, we noticed that animals pretreated with phentolamine appeared to exhibit decreased activity in response to centrally administered NPW-23. Therefore, we placed rats in an Opto-Max activity monitor, and after 1 h of habituation administered saline or phentolamine-HCl intra-arterially 15 min prior to intracerebroventricular injection of saline alone, saline containing 1.0 nmol NPW-23, or saline containing 50 pmol ANG II. Central administration of 1.0 nmol NPW-23 or 50 pmol ANG II (without phentolamine pretreatment) led to an increase in total activity and ambulatory activity, as well as the duration of stereotypy. Phentolamine pretreatment significantly inhibited the ability of both NPW-23 and ANG II to increase behavioral activity (Fig. 5, A-C) .
A dose of the OX 1 R antagonist that we previously demonstrated to significantly compromise the behavioral actions of orexin A (11) significantly blunted, but did not eliminate entirely, the behavioral arousal observed following NPW-23 administration (Fig. 6, A-C) . On the other hand, this dose of OX 1 R receptor antagonist, which in previous studies did not alter basal MAP but did abrogate the central cardiovascular action of orexin A (10), completely blocked the action of NPW-23 to increase MAP in conscious, male rats (Fig. 7) .
DISCUSSION
Neuropeptide W (NPW) is produced in, and influences the membrane potential of, neurons in the PVN, an area of the brain that communicates extensively with preautonomic centers in the brain stem and spinal cord (9, 17, 18, 19) and is important for the regulation of ingestive behaviors (5, 19) . Our laboratory previously reported the ability of exogenously applied NPW to significantly increase both food and water intake during the light phase (1) . In contrast, a study by Mondal et al. (7) revealed the ability of NPW to decrease food intake during the dark phase. These apparently contradictory results on food intake suggest the possibility that NPW's action to increase feeding at a time when the animals are normally at rest and not eating is an indirect action of NPW, perhaps secondary to behavioral arousal. We also have reported the ability of NPW-23 to activate the HPA axis by an action in the parvocellular PVN of the hypothalamus (22) . These findings raise the possibility that NPW similarly affects cardiovascular function as a result of its actions in the central nervous system, in particular, the hypothalamus, to stimulate arousal and general locomotor behavior. The present study demonstrated the ability of exogenously applied NPW to act in brain to increase MAP at doses of 0.3 nmol, 1.0 nmol, and 3.0 nmol. The bell-shaped dose-response observed when monitoring MAP following NPW-23 administration is similar to that observed with other peptides (13, 23) . At this time, we do not understand the mechanism underlying this response. We originally reported (22) that intracerebroventricular administration of NPW-23 did not alter MAP in conscious male rats. Subsequent to the original studies, we realized that by expressing the data as a snapshot at any one sampling time, we were ignoring potential changes from baseline in individual animals. We now analyze the change in MAP from a baseline average taken over 5 or 10 min prior to injections (stable baseline period with no manipulation) compared with the actual MAP in each animal measured at timed intervals following injections. This then controls for the variability between animals in terms of MAP values prior to the intracerebroventricular injections, when only subtle, yet still significant, changes occur.
While recording MAP in these animals, we noticed an increase in total behavioral activity, including locomotion and grooming. Here, we report the ability of centrally administered NPW-23 to increase total behavioral activity, including locomotion and grooming, within the first 10 min following intracerebroventricular administration, with the greatest increase in activity occurring in the 1.0-nmol treatment group. Because the increase in activity temporally correlates with the increase in MAP, we hypothesized that the NPW-induced increase in MAP was secondary to an increase in total behavioral activity. We found that the NPW-induced increase in MAP was absent in anesthetized animals that are no longer able to exhibit increases in activity following NPW administration. However, peptides known to increase MAP through a direct action to increase sympathetic efferent activity, such as ANG II (2), are still able to exert their pressor effects in these anesthetized animals, suggesting the NPW-induced increase in MAP is, in fact, secondary to an increase in behavioral activity and not due to direct activation of sympathetic centers in brain.
While the effect of NPW-23 on locomotor behavior was transient, MAP remained elevated for almost 1 h. This might suggest independent mechanisms underlying these two effects; however, a peptide's action on behavior and MAP may not always follow the same time course. For instance, intracerebroventricular administration of orexin causes an almost immediate increase in mean arterial pressure (10) , and yet stress hormone levels in those animals do not rise until 30 to 45 min later (12) , and significant increases in locomotor behavior similarly take about 30 min to be manifested (11) . The same can be said for nesfatin-1 (23) . Importantly, in the case of orexin (21) and nesfatin-1 (20) , these two peptides have been shown to increase sympathetic nerve activity, even in the anesthetized state. In our hands NPW-23 administration intracerebroventricularly does not alter renal sympathetic nerve activity (Samson WK, Yosten GLC, and Knuepfer MM, unpublished data) or mean arterial pressure (as reported here) in urethane-anesthetized rats and, as reported here, phentolamine pretreatment blocks both the increase in MAP and the increase in locomotor behavior. We also show that the hypertensive effects of NPW in conscious, freely moving rats can be prevented by pretreatment with a mixed ␣ 1 -and ␣ 2 -adrenergic antagonist, phentolamineHCl. However, animals that were pretreated with phentolamine no longer exhibited increases in total behavioral activity, including locomotion and grooming, following central NPW-23 or ANG II administration. This may be the result of phentolamine on arousal centers in the brain, or alternatively, the hypotensive action of the ␣-adrenergic blocking agent.
In 2005, Levine et al. (6) demonstrated, using dual immunostaining, that c-Fos was increased in orexin-containing neurons in the perifornical region of the lateral hypothalamic area (LHA) following central NPW administration (6) . Takenoya et al. (18) also demonstrated very close neuronal interactions between NPW-containing nerve fibers and orexin-containing neuronal cell bodies and nerve fibers in the LHA. Orexin has been shown to play a key role in arousal, as well as in regulation of energy balance (16, 18) . It is possible that the effect of NPW on food intake and cardiovascular function could be mediated through the activation of the orexinergic system. We have demonstrated the ability of orexin A to increase total behavioral activity, ambulatory activity, and duration of stereotypy (11), much like the data presented in this study for NPW-23 central administration. Interestingly, orexin neurons are activated by stress, and CRH can modulate the activity of these neurons. In addition, the infusion of orexin can activate the HPA axis (4, 10) . Orexinergic neurons may integrate information from multiple circuits, including CRH and NPW peptidergic systems, to provide output to stabilize arousal networks (16, 18) . Our laboratory has shown previously that both NPW (1, 22) and orexin (10) administered intracerebroventricularly activated the HPA by increasing CRH release into the hypophyseal portal vessels. The orexinergic system could be a component of the circuitry that contributes to the observed actions of NPW, in particular, on feeding behavior and cardiovascular alterations, or the acute stress response (1, 6, 22) .
Here, we demonstrate that antagonism of the orexin type 1 receptor significantly decreased the behavioral responses to NPW-23 administration. This partial blockade is reminiscent of the effect of the antagonist on orexin A-induced behavior, where a significant reduction was observed, but not a complete reversal of the effect (11) . In that earlier work, we explained the failure to completely reverse the action of orexin A to be due to the involvement of the orexin type 2 receptor. In fact, we demonstrated that the behavioral arousal observed following selective activation of the orexin type 2 receptor with [(Ala 11 , Leu 15 )-orexin B] was not altered by the OX 1 R antagonist, SB-408124 (11) . It is also possible that a longer pretreatment period than that employed here would be necessary to completely abrogate the action of NPW-23 or that a nonselective orexin antagonist would be more effective. Thus, from our current results, we can only suggest that the behavioral arousal observed following NPW-23 administration was due partially to the activation of endogenous orexin-producing neurons in the lateral hypothalamic area, where a close apposition of NPW-23-immunoreactive nerve fibers and orexin-positive cell bodies have been identified (18) .
Pretreatment with the OX 1 R antagonist, however, completely blocked NPW's action to elevate MAP, as it did when administered centrally prior to a pressor dose of orexin A (11).
These results strongly suggest that several of the similar actions of NPW (i.e., stress hormone secretion, behavioral arousal, and MAP elevation) may be mediated by a downstream action of NPW on orexin neurons in the LHA, where anatomical evidence for a possible interaction of the two peptides has been reported (18) .
Perspectives and Significance
Together, our data suggest a modulatory role of NPW on the hypothalamic control of cardiovascular function secondary to its ability to induce behavioral arousal. Our results also point to the importance of considering behavioral arousal as a cause of the increased mean arterial pressure observed in conscious animals following central administration of test substances, in particular, peptides, and not necessarily direct actions of the treatment of central cardiovascular control circuits.
